“salivary biomarker panel for therapeutic monitoring and relapse prediction in head and neck cancers”
Patent Information
- Application Number
- IN202421066127
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2026-10-13
- Estimated Expiration
- 2044-09-02
AI Technical Summary
Current diagnostic and monitoring strategies for head and neck cancers, particularly oral squamous cell carcinoma (OSCC), are invasive, costly, and lack real-time molecular insights, leading to delayed treatment responses and relapse detection, with existing biomarker panels failing to provide dynamic, non-invasive, and OSCC-specific monitoring solutions.
A salivary biomarker panel utilizing miR-1307-5p, CD44v6, KRT4, and PD-L1 derived from salivary extracellular vesicles, integrated with RT-qPCR, to provide a non-invasive, real-time assessment of therapeutic response, relapse risk, and immunotherapy suitability, enabling dynamic patient stratification and clinical decision-making.
Enables real-time, non-invasive monitoring of therapeutic response and relapse prediction, reducing overtreatment, improving patient outcomes by providing actionable molecular insights and proactive clinical interventions.
Abstract
Description
FIELD OF THE INVENTIONThe present invention relates to the field of molecular diagnostics, specifically to asalivary biomarker panel and associated diagnostic kit for therapeutic monitoringand relapse prediction in head and neck cancers, including oral squamous cellcarcinoma (OSCC). The invention pertains to a non-invasive diagnostic solutionthat utilizes a synergistic combination of RNA biomarkers derived from salivaryextracellular vesicles, integrated with a structured analytical workflow for real-timeassessment of therapeutic response, relapse risk, immunotherapy suitability, andpatient prognosis.This invention further relates to diagnostic compositions, in vitro diagnosticmethods, and clinical decision-support tools designed to facilitate dynamic,repeatable monitoring of treatment efficacy and disease progression, offering apractical alternative to conventional tissue biopsies and imaging-basedassessments. The invention has broad applicability in precision oncology,companion diagnostics, and personalized cancer care.BACKGROUND OF THE INVENTIONHead and neck squamous cell carcinomas (HNSCC), including oral squamous cellcarcinoma (OSCC), represent a significant global health burden. According toGlobocan 2022, head and neck cancer accounts for approximately 930,000 newcases annually worldwide, with Asia contributing about 575,000 cases, and Indiaalone reporting nearly 205,000 new cases annually. OSCC is the leading cancer inIndian males, fourth in females, and second overall. However, true incidence islikely underreported. Alarmingly, only 17% of patients are diagnosed at Stage I,with most presenting at advanced stages.Diagnosis in OSCC is typically delayed, often occurring only after symptoms suchas pain, dysphagia, or palpable masses appear. By this time, tumors are usuallylocally advanced, restricting treatment options and necessitating aggressiveinterventions like radical surgery or chemoradiotherapy, which severely affectsurvival and quality of life. Similarly, relapse detection is largely dependent onimaging techniques such as PET-CT or MRI, performed annually which detectrelapse only after tumors have regrown to visible size. These methods fail toidentify early molecular or microenvironmental changes indicative of treatmentresistance or residual disease, resulting in delayed clinical intervention and pooreroutcomes.Current diagnostic and monitoring strategies are heavily reliant on invasive tissuebiopsies and imaging modalities, both of which carry significant limitations. Theseinclude invasiveness, high costs, sampling bias due to tumor heterogeneity, limitedsensitivity for early detection, and inability to provide dynamic or real-timeassessment of therapeutic response. Repeated biopsies are impractical, whileimaging often yields false positives or negatives, leading to delayed or suboptimaltreatment decisions.Treatment planning, especially in advanced OSCC cases, depends heavily onimaging-derived metrics. Neoadjuvant chemotherapy (NACT) is typicallyprescribed based on tumor size and spread, with treatment efficacy retrospectivelyevaluated after multiple cycles using the Response Evaluation Criteria in SolidTumors (RECIST). However, RECIST is a static, delayed metric based onmorphological tumor shrinkage, failing to capture early molecular responses suchas necrosis, immune activation, or microenvironmental shifts. It primarily evaluateslinear changes in tumor diameter, not: Tumor density, Metabolic activity andMolecular alterations. Cannot Differentiate Between Viable and Non-ViableTissue. Insensitive to Pseudoprogression, especially in immunotherapy, tumorsmay temporarily enlarge due to immune infiltration (called pseudoprogression),which RECIST mislabels as progressive disease (PD). Cannot accurately assessBone lesions, Lymphangitis spread and Diffuse mucosal thickening (common inOSCC). This often results in continuation of ineffective therapies, exposing patientsto unnecessary toxicity and delaying potentially curative interventions.Even in early-stage cases, nodal involvement is frequently confirmed only aftersurgical resection via histopathology, necessitating reactive rather than proactivetreatment adjustments. Additionally, some early-stage tumors exhibit aggressivebehavior and metastasize quickly, yet current protocols fail to identify such casesin advance, leading to relapse.Relapse detection remains a significant clinical challenge. While early relapsescould potentially be managed with minimally invasive procedures, most aredetected too late, necessitating full cycles of chemotherapy, radiotherapy, orsurgery, all of which have high cumulative toxicity. Re-radiation is often unfeasibledue to prior tissue damage, and anatomical limitations restrict surgicalinterventions.For patients with inoperable disease, multiple relapses, or resistance to standardtherapies, immunotherapy agents like cetuximab, nivolumab, and pembrolizumabare employed. However, their use still requires PD-L1 expression assessment viainvasive tissue biopsy, creating a paradox where even inoperable patients mustundergo biopsy for treatment eligibility.Despite extensive research into blood and tissue biomarkers, and emerging work insalivary transcriptomics and proteomics, there is no clinically validated, noninvasive biomarker platform that enables real-time therapeutic monitoring or earlyrelapse prediction in HNSCC. Existing diagnostic modalities fail to bridge thiscritical gap, lacking the ability to provide dynamic molecular insights necessary fortimely clinical decision-making.Saliva, as a non-invasive and easily collectible biofluid, offers a promisingalternative for repeated sampling and longitudinal monitoring. Tumor-derivedextracellular vesicles present in saliva contain stable RNA and protein cargoesshielded from degradation, making them ideal candidates for molecular diagnostics.However, to date, there are no clinically translatable salivary biomarker panels ordiagnostic kits specifically tailored for real-time monitoring of therapeutic efficacyand relapse risk in head and neck cancers.Thus, there is an urgent unmet clinical need for non-invasive, repeatable, and realtime molecular tools that enable early prediction of therapeutic response and relapserisk, thereby facilitating personalized treatment strategies and shifting clinicalpractice from reactive to proactive cancer care. The present invention addressesthese challenges through a salivary biomarker panel and diagnostic kit capable ofdynamic monitoring, empowering clinicians with actionable molecular insights toimprove patient outcomes in OSCC.PRIOR ARTSSeveral prior art references disclose methods and compositions related to cancerbiomarker detection using nucleic acid or protein-based assays. However, thesedisclosures fail to address the specific diagnostic and clinical management needs oforal squamous cell carcinoma (OSCC), particularly in the context of non-invasive,repeatable, and dynamic therapeutic monitoring and relapse prediction.1. US20090317820 - Micro-RNA Profile in Human Saliva and Its Use forDetection of Oral CancerAbstract Extract:"The present invention provides for the first time the detection of micro-RNA inhuman saliva and the correlation between such micro-RNA and oral cancers. Thepresent invention therefore provides methods and kits for diagnosing oral cancersby examining pertinent micro-RNA in saliva."Key Focus:- The reference introduces the detection of salivary micro-RNA as adiagnostic approach for oral cancers.- The scope is primarily identification-focused, aiming to establishcorrelation between detected micro-RNA and disease presence.- The invention proposes a saliva-based detection method but does not extendbeyond initial diagnosis.Key Limitations:A. Fragmented Biomarker Information Without Contextual Integration:- While it mentions micro-RNA detection, the invention does not propose acombinatorial biomarker strategy that can provide holistic insights intodisease status, treatment suitability, or patient-specific therapeuticpathways.B. Absence of a Synergistic Biomarker Combination:While micro-RNA detection is disclosed, the invention lacks a synergisticbiomarker panel designed to provide holistic, stratified clinical outputs(therapeutic response, relapse risk, treatment suitability) derived fromcombinatorial expression analysis.C. Inadequate Clinical Decision-Making Support:- The disclosed approach lacks mechanisms that would assist healthcareprofessionals in interpreting biomarker data for guiding treatmentdecisions.- There is no actionable framework to determine which patients will benefitfrom specific therapies, nor does it facilitate risk-based stratification foraggressive disease management.D. Absence of Real-Time Monitoring and Dynamic Assessment:- The invention is restricted to a single-point diagnostic snapshot, offeringno provisions for monitoring therapeutic response or detecting relapseduring or after treatment.- Clinicians are left without the means to track disease progression ortherapy efficacy in a repeatable, practical manner.E. No Workflow or Motivation for Clinical Adoption:- The lack of structured interpretation models and absence of a practicalworkflow means practitioners have limited utility in applying the disclosedmethod for routine clinical practice.- The information provided does not bridge the gap between moleculardetection and real-world clinical applicability, leaving healthcareproviders without tools to confidently tailor treatments.F. Sampling Approach Remains Incomplete for Comprehensive DecisionSupport:- Although saliva is used, the method does not leverage extracellular vesicleenrichment, which is critical for ensuring reliable and disease-specificRNA profiling.- The invention does not address tumor heterogeneity, biomarker stability,or ensure reproducibility of results necessary for effective clinicalmonitoring.G. Non-invasive Sample Collection Without Clinical Utility Translation:- Although the reference utilizes saliva, a non-invasive sample, theinvention does not translate this advantage into a clinically actionableplatform. The method fails to bridge the gap between molecular detectionand effective clinical decision-making workflows.- There is no structured interpretation framework or monitoring utility,resulting in underutilization of the non-invasive sampling advantage,leaving practitioners without real-time, patient-specific guidance fortherapeutic management.2. US20210032344A1 - Multiplex RNA Biomarker Panels for CancerDetectionAbstract Extract:"Multiplexed panels of RNA biomarkers for detecting cancer are provided. Thepanels can be configured for detecting a variety of cancer types and subtypes.Methods of using these panels for cancer detection, prognosis, and therapyselection are also provided."Key Focus:- The invention discloses multiplex RNA biomarker panels designed for thedetection of various cancers through nucleic acid amplification-basedassays.- The emphasis lies on developing RNA biomarker panels applicable to abroad oncology spectrum, including-but not limited to-lung, breast, andcolorectal cancers.- While it introduces multiplexing RNA markers, the disclosure is detectionfocused and does not extend into dynamic monitoring or therapeuticdecision-making frameworks.- The sample matrices predominantly involve blood, serum, and tissuesamples, not saliva or salivary extracellular vesicles.Key Limitations:A. Non-Specific Biomarker Composition:- The biomarker panels disclosed are generic and designed for multi-cancerdetection, lacking OSCC-specific molecular signature alignment.- The panel composition does not integrate biomarkers uniquely validatedfor oral squamous cell carcinoma (OSCC) or for head and neck cancers,failing to address anatomical and pathological nuances specific to thesediseases.B. Inappropriate Sample Type for OSCC Monitoring:- The method relies on serum, plasma, or tissue samples, which are invasiveand thereby painful for frequent and longitudinal assessments.- The diagnostic approach overlooks saliva as a biofluid, which isanatomically and biologically better suited for non-invasive monitoring ofhead and neck cancers.C. Absence of Stratified Risk Interpretation Framework:- The invention does not offer a structured interpretation framework tosupport clinicians in tailoring therapies based on molecular profiles,rendering it insufficient as a clinical decision-support tool.D. No Provision for Real-Time Monitoring or Longitudinal Assessment:- The disclosed methods capture a single-point diagnostic snapshot, withoutenabling dynamic assessment of therapy response or proactive relapsedetection.- The invention lacks workflows or methodologies that would allow forrepeat, real-time monitoring of treatment efficacy, a critical gap formanaging OSCC patients who require frequent follow-ups.E. Lack of OSCC-Centric Clinical Validation:- The invention does not present any clinical validation data specific toOSCC or head and neck cancers.- The multiplex panels are not demonstrated for application in salivaryextracellular vesicles or OSCC patient cohorts, limiting their practicalutility in this clinical domain.F. Missed Opportunity to Leverage Saliva's Diagnostic Advantages:- Despite saliva being a highly relevant and non-invasive biofluid for oraland head and neck cancers, the invention does not utilize salivaryextracellular vesicle-derived RNA, thereby missing a key opportunity forreal-time, patient-friendly monitoring.G. Lack of Synergistic Biomarker Panel Composition:- Although multiplex PCR is disclosed, the invention does not present avalidated, synergistic biomarker combination specifically tailored forOSCC, nor does it enable outcome stratification through integratedexpression analysis.3. US9157126B2, WO2019 / 171110A1, US2010 / 0099102A1 - SalivaryProtein Biomarkers for Oral and Head and Neck CancersOverview & Focus:- These prior arts disclose salivary protein biomarkers such as MMP9, CD44,Cyclin D1, and others, aimed at the early detection of oral squamous cellcarcinoma (OSCC) and head and neck squamous cell carcinoma (HNSCC).- The primary objective is to develop non-invasive saliva-based tests forinitial cancer identification.- However, these inventions are primarily used for screening, limited toidentifying disease presence without addressing ongoing monitoring,treatment suitability, or relapse risk assessment.Key Limitations:A. Limited to Protein Markers Without RNA-Level Molecular Insights:- The disclosed biomarker panels are confined to soluble protein markers,missing the diagnostic and prognostic advantages of RNA biomarkersderived from salivary extracellular vesicles.- The inventions fail to capture tumor-specific RNA signatures that providedeeper insights into disease biology, therapy response, or resistance.B. No Combined Biomarker Interpretation for Patient Stratification:- Although multiple protein markers are mentioned, the references do notpresent a combinatorial or synergistic approach to interpret biomarkertrends for stratifying patients into clinical categories.- As a result, the findings do not provide sufficient guidance to cliniciansregarding which treatment regimen would be most effective for aparticular patient profile.C. Absence of a Synergistic Multi-Marker Panel for ClinicalStratification:- The inventions list multiple protein biomarkers but do not disclose asynergistic combination configured to produce stratified,reproducible clinical insights essential for guiding therapy decisionsand predicting relapseD. Lack of Therapeutic Monitoring and Relapse Prediction Capability:- The inventions are designed as single-point diagnostic tools, offering nomechanisms for repeatable, real-time monitoring of therapy response orearly relapse detection.- This limits their applicability in dynamic clinical decision-makingworkflows, where ongoing assessment of disease status is critical.E. No Practical Kit-Based Workflow for Clinical Adoption:- The prior arts do not provide a diagnostic kit or standardized workflowintegrating sample collection, biomarker extraction, detection, and resultinterpretation.- Without such a platform, clinical adoption becomes impractical, ashealthcare providers are left without a streamlined process for routinepatient management.F. Non-Utilization of Extracellular Vesicle Enrichment:- Although saliva is used as a sample medium, the methods do notincorporate extracellular vesicle isolation, which is essential for ensuringbiomarker stability, specificity, and reproducibility.- This omission reduces the clinical reliability of the assay, especially inheterogeneous tumor environments.G. Fail to Translate Non-Invasive Sampling into Actionable ClinicalUtility:- While the prior arts utilize saliva as a non-invasive fluid, the inventions donot bridge the gap between molecular detection and effective clinicaldecision-making.- The diagnostic outputs lack the clarity and depth of information requiredby clinicians to make treatment guidance decisions, leaving an unmet needfor a solution that converts biomarker data into practical patientmanagement strategies.4. Startups and Emerging Products:Startups such as Erly Sign (India), SalivaChecker (Japan), and OrisDx (USA)focus primarily on early screening and diagnostic detection of oral cancers. Theydo not offer solutions for dynamic therapeutic monitoring or relapse prediction.SummitDX's HNKlear (USA) is another such product; however, it remainslimited in scope to protein-based assays and lacks a validated RNA-proteincomposite biomarker panel integrated with a structured risk scoring system asclaimed in the present invention.Thus, the prior art references fail to disclose or enable a biomarker panelcomposition and diagnostic kit tailored to salivary extracellular vesicles, capable ofproviding real-time therapeutic monitoring and relapse prediction in OSCCpatients.There remains an unmet need to provide a Salivary Biomarker Panel forTherapeutic Monitoring and Relapse Prediction in Head and Neck Cancersthat enables:- non-invasive, repeatable, and real-time molecular assessment of therapeuticresponse and relapse risk;- integration of a validated combination of biomarkers specific to OSCCbiology;- dynamic patient stratification based on composite risk scoring;- clinical decision support through structured and actionable reportingworkflows.LIMITATIONS OF PRIOR ARTThe existing diagnostic and monitoring tools for head and neck cancers, includingoral squamous cell carcinoma (OSCC), suffer from one or more of the followingsignificant limitations:1. Absence of Non-Invasive, OSCC-Specific Diagnostic Tools: Currentapproaches lack non-invasive diagnostic or monitoring solutionsspecifically designed for OSCC and head and neck cancers, particularly fordynamic and repeatable assessments.2. Dependence on Invasive and Costly Modalities: Tissue biopsies andimaging techniques like PET-CT and MRI are invasive, resource-intensive,and impractical for frequent or longitudinal monitoring of tumorprogression and therapeutic response.3. Inability to Capture Early Molecular Changes: Imaging modalities (CT,MRI, PET-CT) detect gross anatomical changes but are insensitive to earlymolecular or microenvironmental responses, leading to delayed detection ofrelapse or resistance. They are also prone to false positives / negatives andprovide only static snapshots of disease status.4. Delayed Assessment of Treatment Efficacy (RECIST Limitations):RECIST-based radiographic criteria evaluate response solely on tumor sizereductions, failing to capture biological parameters such as necrosis,metabolic activity, early resistance, or immune responses, resulting incontinued administration of ineffective therapies.5. Insufficient Tools for Immunotherapy Decision-Making: Immunecheckpoint inhibitor therapies (e.g., nivolumab, pembrolizumab) depend oninvasive PD-L1 tissue testing. For inoperable tumors, this necessitates eitherimpractical biopsies or empiric, unguided treatment administration.6. Inadequate Early Relapse Prediction: Existing tools cannot detect relapseat a molecular level before overt tumor regrowth, delaying timelyinterventions and adversely affecting survival outcomes.7. Inter-Observer Variability and Tumor Heterogeneity: Imaging andbiopsy-based assessments are subject to interpretive variability and fail toaccount for intra-tumoral heterogeneity, compromising reproducibility anddiagnostic accuracy.8. Delayed Diagnosis Leading to Advanced-Stage Detection: Conventionaldiagnostic workflows often detect OSCC only after symptomaticpresentation or when tumors have reached a size visible on imaging,limiting treatment options and prognosis.9. Delayed and Inefficient Relapse Detection: Surveillance relies onperiodic imaging with substantial intervals, failing to identify subtlemolecular recurrences, which postpones necessary clinical interventions.10. Lack of Proactive, Real-Time Molecular Monitoring Tools:Existing diagnostic approaches are inherently reactive, identifying diseaseprogression or relapse only after anatomical changes become radiologicallydetectable or clinical symptoms manifest. These methods fail to provideproactive, early-warning insights into molecular or microenvironmentalchanges indicative of treatment resistance or impending relapse. Without anon-invasive, real-time monitoring tool, clinicians are unable to intervenepreemptively, resulting in delayed therapeutic adjustments andcompromised patient outcomes.11. Lack of Real-Time, Continuous Monitoring Capability: Existingmethods do not support dynamic, non-invasive monitoring of diseaseprogression, resulting in missed opportunities for timely therapeuticadjustments.12. Limited Personalization of Immunotherapy Planning: Currentdiagnostic tools offer no efficient, minimally invasive method to determinea patient's potential responsiveness to immunotherapy agents.13. Absence of Clinically Validated Salivary Biomarker Panels forHNSCC: There is a lack of companion diagnostic kits utilizing salivaryextracellular vesicle-derived biomarkers validated for therapeuticmonitoring and relapse prediction in head and neck cancers.14. Redundancy of Invasive and Ineffective Treatment Cycles: Multipleinvasive procedures and imaging studies often fail to optimize treatmentstrategies, resulting in unnecessary treatment cycles, increased patientsuffering, and higher healthcare costs.15. Lack of Validated Combinatorial Salivary Biomarker Panels: Prior artdoes not disclose a clinically validated combination of multiple salivarybiomarkers specifically derived from extracellular vesicles tailored forOSCC diagnostic and monitoring applications.16. Lack of Synergistic Biomarker Combinations for Stratified ClinicalOutputs: While prior art references may disclose individual biomarkers orgeneric panels, they fail to propose a synergistic combination of salivaryextracellular vesicle-derived biomarkers configured to collectively stratifypatients into actionable clinical categories such as responders, nonresponders, high relapse risk, and immunotherapy suitability. This lack ofcombinatorial approach limits clinical utility and diagnostic accuracy.17. Inability to Simultaneously Evaluate Key Clinical Parameters: Existingsolutions do not enable concurrent assessment of chemotherapy response,relapse risk, and immunotherapy suitability in a single, unified testworkflow.18. Absence of a Practical, Clinician-Friendly Workflow for Real-WorldAdoption: Existing diagnostic modalities and biomarker assays lack astandardized, reproducible workflow that clinicians can easily adopt inroutine practice. The gap persists between molecular detection andactionable clinical insights, leaving healthcare providers without reliabledecision-support tools to guide personalized therapy planning and patientcounselling.19. Limited to Single-Stage Applications: Most existing technologies areconstrained to either early detection or post-treatment monitoring, lackingadaptability for continuous use across diagnosis, treatment assessment, andlong-term follow-up.Given these cumulative limitations, there remains a critical unmet need for a noninvasive, saliva-based companion diagnostic kit that integrates a synergisticbiomarker panel with a practical clinical workflow, enabling real-time therapeuticmonitoring, early relapse prediction, and stratified patient management in head andneck cancers. Such a solution must facilitate personalized, repeatable, and dynamicclinical decision-making throughout the patient's care continuum.OBJECTIVES OF THE INVENTIONThe primary objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that enables a non-invasive, saliva-based prognostic solution utilizingextracellular vesicle-derived biomarkers for real-time monitoring of therapeuticresponse and prediction of relapse in patients with head and neck cancers;comprising a biomarker panel uniquely validated for salivary extracellular vesicles,specifically tailored to oral squamous cell carcinoma (OSCC) biology..Another objective of the present invention is to provide a Salivary Biomarker Panelfor Therapeutic Monitoring and Relapse Prediction in Head and Neck Cancers, thatenables detection of disease progression and relapse at a molecular level, evenbefore clinical symptoms or radiological signs become apparent, therebyfacilitating earlier clinical intervention.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that overcomes the limitations of RECIST-based radiological responseassessments, which rely on tumour size changes and fail to capture early molecularindicators of treatment resistance or relapse, thereby enabling proactive and timelyclinical decision-making.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that enables stratification of patients as responders or non-responders totherapy, facilitating early identification of non-responders to minimize unnecessarytreatment cycles.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that enables non-invasive assessment of immunotherapy suitability,addressing cases where tissue biopsies are impractical or contraindicated.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that supports repeat, longitudinal saliva sampling for dynamic diseasemonitoring without the need for invasive biopsies or frequent imaging.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that assists clinicians in optimizing treatment strategies throughpersonalized, real-time molecular insights into therapy response and relapse risk;by enabling simultaneous assessment of chemotherapy response, relapse risk, andimmunotherapy suitability through a single, integrated diagnostic workflowYet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that minimizes treatment-related toxicity and healthcare burden byidentifying ineffective treatments early in the therapeutic timeline.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that enables early relapse prediction through detection of molecular andmicroenvironmental changes, even in the absence of radiological or symptomaticevidence.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that supports continuous use across the clinical care continuum-spanninginitial diagnosis, active treatment monitoring, and long-term relapse surveillance.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that addresses the inability of imaging modalities (CT, MRI, PET-CT) todetect early molecular relapse or subtle biological changes, by capturing dynamicbiomarker expression profiles through non-invasive salivary analysis.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that empowers healthcare providers with a reliable decision-support tool,enabling evidence-based treatment selection and timely therapeutic adjustments,thereby enhancing clinical confidence and improving patient outcomes.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that shifts disease management from reactive interventions based on latestage symptomatic or radiological detection to proactive, molecularly guidedclinical decision-making, allowing for early therapeutic intervention and improvedprognosis.Yet another objective of the present invention is to provide a Salivary BiomarkerPanel for Therapeutic Monitoring and Relapse Prediction in Head and NeckCancers, that enables prognostication by correlating biomarker signatures withpatient survival outcomes, thereby supporting risk stratification and long-termclinical planning.SUMMARY OF THE INVENTIONThe present invention provides a technical solution to the unmet clinical need fornon-invasive, real-time monitoring of therapeutic response and relapse predictionin patients with head and neck cancers, particularly oral squamous cell carcinoma(OSCC). This is achieved through a salivary biomarker panel and a companiondiagnostic kit that enables dynamic, molecular-level assessment of treatmentefficacy and disease progression.The invention integrates a synergistic combination of four salivary biomarkers-miR-1307-5p, CD44v6, KRT4, and PD-L1-whose collective expression profilesprovide comprehensive insights into chemotherapy responsiveness, relapse risk,immunotherapy suitability, and overall prognosis. These biomarkers are detectedfrom RNA extracted from salivary extracellular vesicles and / or cellular fractionsusing reverse transcription quantitative polymerase chain reaction (RT-qPCR).To operationalize this biomarker panel, the invention provides a diagnostic kitcomprising:- Biomarker-specific primers / probes for RT-qPCR amplification;- Reagents for RNA isolation, cDNA synthesis, and quantitative detection;- Reference RNA control samples for baseline normalization;- A software module configured to process expression data, compute foldchange values, generate composite risk scores, and stratify patients intoclinically actionable categories.The technical solution provided by this invention eliminates reliance on invasivebiopsies and imaging-based assessments, which are limited by sampling bias, highcost, and delayed responsiveness. By leveraging non-invasive saliva sampling, theinvention allows for repeatable, longitudinal monitoring across the patient'streatment timeline, providing clinicians with dynamic, evidence-based insights toguide therapeutic decision-making and timely intervention.Unlike prior art that focuses solely on early detection or isolated biomarkerassessments, the present invention offers a validated, combinatorial biomarkersignature supported by a standardized detection platform, addressing critical gapsin precision oncology for head and neck cancers.BRIEF DESCRIPTION OF DRAWINGSThe accompanying drawings illustrate certain embodiments of the present inventionand, together with the detailed description, serve to explain its principles:- Figure 1 illustrates box-violin plots of ChemoScores in chemotherapyresponders and non-responders, together with survival plots showingcorrelation between ChemoScore values and progression-free survival.- Figure 2 shows relapse scores in patients with and without relapse, alongwith survival plots demonstrating correlation between RelapseScore andprogression-free survival.- Figure 3 presents ImmunoScores in immunotherapy responders and nonresponders, together with validation of predictive performance in the patientcohort.- Figure 4 illustrates the integration of ChemoScore, RelapseScore, andImmunoScore into a composite Overall Risk Score, with associated survivalanalysis and stratification of patients into low, moderate, high, and veryhigh-risk categories.DETAILED DESCRIPTION OF THE INVENTIONThe present invention relates to a Salivary Biomarker Panel for TherapeuticMonitoring and Relapse Prediction in Head and Neck Cancers, wherein asynergistic combination of four specific biomarkers-miR-1307-5p, CD44v6,KRT4, and PD-L1-is employed to provide a comprehensive, non-invasivediagnostic solution. The inventive biomarker panel has been specifically designedto address the unmet clinical need for dynamic, repeatable, and molecular-levelmonitoring of therapeutic response (refers to the patient's biological response tostandard-of-care treatments, including chemotherapy, radiotherapy, and targetedtherapies), relapse risk (likelihood of disease recurrence or progression after initialtherapy), immunotherapy suitability (patient's potential responsiveness toimmunotherapy agents), prognosis, and survival prediction ((anticipated diseasetrajectory and survival probability, reflecting tumor aggressiveness and therapeuticresponsiveness) in patients with oral squamous cell carcinoma (OSCC) and relatedhead and neck malignancies.Unlike conventional approaches that rely on invasive tissue biopsies, static imagingmodalities, or singular biomarker assessments, the present invention leverages thesynergistic expression profiles of these four biomarkers, derived from salivaryextracellular vesicles and / or cellular fractions, to generate actionable clinicalinsights. The combined evaluation of these biomarkers enhances diagnosticspecificity, predictive accuracy, and clinical utility across multiple stages of patientcare.The invention is operationalized through specific embodiments, each designed toillustrate how the synergistic application of the biomarker panel enables a noninvasive, clinically translatable platform for therapeutic monitoring and relapseprediction. These embodiments describe, by way of example, the biomarker panelcomposition, diagnostic kit configuration, analytical workflows, and clinicalmethodologies that implement the invention.It is to be understood that the embodiments described herein are provided solely toexemplify the invention's principles and are not intended to limit the scope ofprotection sought. The invention encompasses all variations, modifications, andequivalents that derive from the underlying inventive concept of employing asynergistic biomarker panel for dynamic, real-time, non-invasive monitoringof head and neck cancers.The following sections describe each embodiment in detail, elucidating how theinvention's components work together to deliver the claimed diagnosticadvantages.Embodiment 1: Salivary Biomarker Panel for Therapeutic Monitoring andRelapse Prediction in Head and Neck CancersEmbodiment 1 relates to a Salivary Biomarker Panel for Therapeutic Monitoringand Relapse Prediction in Head and Neck Cancers, providing a non-invasivemolecular diagnostic solution for assessing therapeutic response, predicting relapse,determining immunotherapy suitability, and evaluating prognosis and survivalprediction, particularly in patients with oral squamous cell carcinoma (OSCC).This embodiment is based on a synergistic combination of four clinically validatedRNA biomarkers:- miR-1307-5p,- CD44v6,- KRT4,- PD-L1.These biomarkers are quantified from RNA extracted from salivary extracellularvesicles and / or cellular fractions using reverse transcription quantitativepolymerase chain reaction (RT-qPCR).The inventive merit of this embodiment lies in the synergistic expression profileof these four biomarkers, which, when analyzed collectively, enables precise andactionable stratification of patients across multiple clinical dimensions, overcomingthe limitations of single-marker diagnostics.Functional Interpretation of Biomarker Thresholds:- miR-1307-5p ≥ 2.0-fold: Indicates chemosensitivity and predicts therapeuticresponse, disease aggressiveness and survival.- CD44v6 ≥ 2.0-fold: Indicates high relapse risk and disease aggressiveness andsurvival.- KRT4 ≤ 1.0-fold: Indicates chemosensitivity and predicts therapeuticresponse.- PD-L1 ≥ 1.0-fold: Indicates immunotherapy suitability.Multifactorial Clinical Stratification Enabled by the Panel:The invention enables patient stratification into therapeutic response categories,comprising:- Responder (who demonstrates effective therapeutic response and reducedrelapse risk)- Non-responder (who demonstrates ineffective therapeutic response andelevated relapse risk)- High relapse risk- Immunotherapy-suitableAdditionally, based on the integrated interpretation of combined biomarkerexpression trends, a prognostic outcome assessment is derived to classify patientsunder 'Poor prognosis', indicative of adverse survival likelihood and aggressivedisease biology.This hierarchical stratification provides dynamic, actionable insights during activetreatment monitoring while also delivering conclusive prognostic evaluations toinform long-term clinical management strategies.Measurement and Stratification Workflow:RNA is isolated from salivary extracellular vesicles and cellular fractions,leveraging the non-invasive, easily accessible nature of saliva to facilitate repeatedsampling for longitudinal disease monitoring. The extracted RNA undergoes RTqPCR analysis, offering high sensitivity and specificity for quantifying biomarkerexpression fold-change values relative to baseline controls. These expression valuesare normalized and processed to compute individual biomarker-specific scores,which are subsequently integrated into a composite risk score. Based on this score,patients are stratified into clinical categories indicative of therapeutic response,relapse risk, immunotherapy suitability, and overall prognosis. The scoring isexecuted through a structured algorithmic model designed to ensure objective,reproducible, and real-time interpretation, thereby supporting informed clinicaldecision-making.The invention employs a structured biomarker interpretation framework thatintegrates multiple expression-based scores to enable precise clinical stratificationof head and neck cancer patients. The scoring methodology is designed to predictchemotherapy responsiveness, relapse risk, and immunotherapy suitability byquantifying and processing biomarker expression levels from saliva-derivedextracellular vesicle RNA.- Chemotherapy Response (ChemoScore) is evaluated by analyzing theexpression of miR-1307-5p (log₂-transformed fold change) and KRT4 (inversesquare root-transformed expression), with weighting factors assigned based onclinical correlations established during model development. Figure 1 demonstratesthat ChemoScore differentiates chemotherapy responders from non-responders,with higher scores associated with resistance to therapy. Validation confirmedpredictive accuracy and correlation with progression-free survival, supporting itsrole as a biomarker for therapy guidance.- Relapse Risk (RelapseScore) is determined through the log₂-transformedexpression patterns of CD44v6, indicating disease aggressiveness and propensityfor recurrence. Figure 2 illustrates that patients who relapsed exhibited higherRelapseScores, with validation confirming predictive accuracy and correlation withinferior survival outcomes. This supports the utility of RelapseScore for earlyrelapse risk identification.- Immunotherapy Suitability (ImmunoScore) is assessed by quantifying PD-L1expression, processed through inverse-transformation and log₂ normalization toevaluate the potential benefit of immune checkpoint inhibitor therapies. Figure 3shows that ImmunoScore distinguishes immunotherapy responders from nonresponders, with higher scores correlating with clinical benefit and validationconfirming predictive accuracy.The individual scores derived from each biomarker are normalized and integratedusing a weighted linear regression framework to produce a Composite Risk Score.This composite score enables categorization of patients into eight clinicalstratification categories:1. Responder - No relapse - Immuno suitable2. Responder - No relapse - Immuno not suitable3. Non-responder - No relapse - Immuno suitable4. Responder - Relapse - Immuno suitable5. Non-responder - Relapse - Immuno suitable6. Responder - Relapse - Immuno not suitable7. Non-responder - No relapse - Immuno not suitable8. Non-responder - Relapse - Immuno not suitableSubsequently, patients are further classified into Low Risk, Moderate Risk, HighRisk, and Very High-Risk categories, aiding clinicians in optimizing treatmentpathways and follow-up protocols. Figure 4 depicts the integration of ChemoScore,RelapseScore, and ImmunoScore into a composite Overall Risk Score, validatedwith high predictive accuracy and showing that higher scores correlate with adversesurvival outcomes. This establishes the Overall Risk Score as a robust predictiveand prognostic tool for stratifying patients.This interpretative scoring methodology is implemented through a proprietaryalgorithm that computes these scores and stratifications in an objective,reproducible manner, enabling its integration into clinical workflows and electronicmedical reporting systems, or alternatively, manual interpretation usingstandardized score charts.The biomarker panel addresses prior diagnostic limitations by enabling real-timemolecular monitoring of therapy response, early relapse prediction, and noninvasive sample collection, thereby reducing overtreatment and guiding precisiononcology interventions. Unlike tissue or blood-based assays, this inventionleverages saliva-derived extracellular vesicles for stable, tumor-specific RNAprofiling. Its synergistic multi-marker approach, coupled with integrated scoring,allows simultaneous assessment of therapeutic response, relapse risk, andimmunotherapy suitability, providing actionable insights for dynamic clinicaldecision-making.Summary Table of Biomarker Interpretations:TableClinical Case Studies and ValidationThe clinical performance of the Salivary Biomarker Panel for TherapeuticMonitoring and Relapse Prediction in Head and Neck Cancers was validatedthrough patient case studies, demonstrating the predictive accuracy, clinicalapplicability, and translational potential of the invention.The following working examples illustrate the technical implementation of theinvention, validating its clinical applicability and predictive accuracy in real-worldpatient scenarios. These examples demonstrate how biomarker expression profilescorrelate with therapeutic response, relapse risk, and immunotherapy suitability.Table 1: Patient Biomarker Profiles and Clinical StratificationFootnote: Overall Risk 1 denotes: Low risk, 2: Moderate risk, 3: High risk, 4: Very high riskClinical Case Studies Description and ValidationCase Study 1: AS104 - High Relapse Risk Non-Responder withImmunotherapy SuitabilityA 54-year-old male diagnosed with buccal mucosa squamous cell carcinomaunderwent neoadjuvant chemotherapy (Cisplatin, Docetaxel, Cetuximab). Pretreatment salivary biomarker profiling revealed:- Chemo Score:3.96- Relapse Score:388.02- Immuno Score: 2.09- Overall Score: 3- The scoring algorithm stratified the patient as a non-responder tochemotherapy, with high relapse risk and high immunotherapysuitability. Despite standard treatment, the patient relapsed within 12months, validating the predictive power of the biomarker panel. Initiationof immunotherapy post-relapse has resulted in clinical improvement.Case Study 2: AS141 - Aggressive Disease with Poor ImmunotherapyResponseA 56-year-old male with carcinoma of the buccal mucosa and retromolar trigonewas started on neoadjuvant chemotherapy (Docetaxel, Cisplatin, 5-FU) combinedwith Pembrolizumab. Biomarker analysis revealed:- Chemo Score: 3.36- Relapse Score:4803.93- Immuno Score: 0.46- Overall Score: 4The algorithm identified the patient as a non-responder with high relapse risk andlow immunotherapy suitability. The patient succumbed to disease within sixmonths, underscoring the panel's predictive accuracy in identifying non-beneficialtherapy paths.Case Study 3: L37 - Low Relapse Risk with High Immunotherapy SuitabilityA 44-year-old male diagnosed with buccal mucosa carcinoma underwent combinedNACT and immunotherapy. Biomarker expression:- Chemo Score: 0.06- Relapse Score: 0.04- Immuno Score: 12.82- Overall Score: 1- Classified as a low-responder to chemotherapy but highly suitable forimmunotherapy, the patient achieved a complete response (T0N0) afterimmunotherapy and surgery, with no recurrence observed during follow-up.Case Study 4: AS207 - Favorable Low-Risk Profile, Complete ResponseA 60-year-old male with carcinoma of the tongue and floor of mouth showed:- Chemo Score: 1.66- Relapse Score: 0.35- Immuno Score: 0.01- Overall Score: 1The algorithm classified the patient as a low-responder to chemotherapy with lowrelapse risk and low immunotherapy suitability. Post-chemotherapy, a completeclinical response was achieved, eliminating the need for surgical intervention.Case Study 5: L13 - Complex CasesA 53 year- old male with squamous cell carcinoma of right buccal mucosashowed:- Chemo Score: 8.94- Relapse Score: 0.29- Immuno Score: 9.38- Overall Score: 2The algorithm classified the patient as a low-responder to chemotherapy with lowrelapse risk and high immunotherapy suitability. Post-chemotherapy, a partialclinical response was achieved by eliminating the need for surgical intervention.However, there was an increase in the tumour lesion size post post chemotherapyand the patient had to undergo surgery.Interpretation of Case Studies:- Non-responders with High Relapse Risk (AS104, AS141): Thebiomarker panel accurately flagged patients with elevated miR-1307-5pand CD44v6 levels as non-responders and high relapse risk. Earlyimmunotherapy could have been prioritized in these cases.- Low-Responder but Immunotherapy-Suitable (L37): Despitesuboptimal chemotherapy response, PD-L1expression ≥1.0-fold guided theeffective use of immunotherapy, resulting in clinical remission.- Favorable Low-Risk Profile (AS207): Biomarker-guided insightsidentified a patient with minimal relapse risk and low immunotherapysuitability, aligning with observed complete response post-chemotherapy.- Complex Cases (L13): The biomarker panel correctly identified a patientunlikely to respond to chemotherapy but suitable for immunotherapy.Delayed immunotherapy initiation led to suboptimal outcomes,underscoring the panel's utility in early clinical decision-making.These cases validate the predictive capacity, stratification accuracy, andpractical utility of the biomarker panel in real-time therapeutic monitoring andrelapse prediction. They illustrate how molecular insights derived from salivarybiomarkers can guide proactive clinical decisions, reduce overtreatment, andimprove patient outcomes.Summary of Validation CohortThe validation cohort comprised 186 patients with head and neck squamous cellcarcinoma (HNSCC), aged between 29 and 75 years, including both male andfemale patients. The majority had oral squamous cell carcinoma, with diseasestages ranging from early (Stage I) to advanced (Stage IVb). Etiologicalbackgrounds included smokeless tobacco use, smoking, and non-habituated cases.Treatment modalities included neoadjuvant chemotherapy (NACT) using regimenssuch as TPF, DCF, and platinum-based combinations, adjuvant chemotherapy,radiotherapy, and / or immunotherapy (agents including nivolumab, pembrolizumab,cetuximab). Clinical outcomes were recorded in terms of relapse, progression-freesurvival, and vital status.These baseline and treatment details provided the clinical framework for correlatingpatient profiles with the calculated ChemoScore, RelapseScore, and ImmunoScore,and for validating the composite risk score model.Comparative Analysis of Predictive Scores and Clinical OutcomesThis table presents the ChemoScore, RelapseScore, and ImmunoScore for eachpatient, together with the corresponding predictions generated by the presentinvention's model, alongside assessments by RECIST criteria and histopathology(HPE). It also records months to relapse, actual clinical outcomes, and indicateswhether the predictions of present invention were concordant with conventionalclinical and pathological evaluations or matched the observed real-world outcomesTableThe results in above table demonstrate that the present invention's integratedscoring framework - combining ChemoScore, RelapseScore, and ImmunoScoreinto an Overall Risk Score - consistently aligned with actual clinical outcomesand, in many cases, outperformed conventional assessment methods such asRECIST criteria and histopathology (HPE).By capturing complementary dimensions of therapeutic response, relapse risk, andimmunotherapy suitability, the combined scores provided a synergistic assessmentthat improved prognostic accuracy and patient stratification compared to any singlemeasure. ImmunoScore, where applicable, showed concordance with gold-standarddiagnostic markers, reinforcing the robustness of the integrated model.The Overall Risk Score effectively classified patients into four categories (1: Lowrisk, 2: Moderate risk, 3: High risk, 4: Very high risk), with higher scores correlatingwith poorer progression-free survival and higher relapse rates. This synergy enablesclinicians to make earlier, more precise, and personalised treatment and follow-updecisions, maximising therapeutic benefit while reducing unnecessaryinterventions.Table 3: Comparative Analysis of Present Invention vs. Prior ArtsScope of Sample Types and Molecular Detection LevelsThe biomarker panel comprising miR-1307-5p, CD44v6, KRT4, and PD-L1, asdescribed herein, is applicable for:(A) Predicting poor prognosis and survival outcomes,(B) Assessing therapeutic efficacy of chemotherapeutic agents including platinumdrugs, taxols, 5-fluorouracil, doxorubicin, cetuximab, methotrexate, radiotherapy,and immunotherapy,(C) Identifying localized or metastatic disease progression, and(D) Evaluating relapse propensity in head and neck cancer patients compared tocontrol groups.The biomarker expression profiles can be analyzed from diverse biological sources,including plasma, saliva, and tissue / cellular compartments such as the membrane,cytoplasm, nucleus, and nuclear membrane. Moreover, detection is feasible at theDNA, RNA, and protein expression levels, individually or in any combinationthereof, thereby enabling comprehensive molecular characterization suited fordiverse diagnostic workflows.Embodiment 2: Diagnostic Kit for Therapeutic Monitoring and RelapsePrediction in Head and Neck CancersEmbodiment 2 provides a diagnostic kit embodied with the salivary biomarkerpanel as described in Embodiment 1, specifically designed for non-invasivemonitoring of therapeutic response and predicting relapse in patients with head andneck cancers, particularly oral squamous cell carcinoma (OSCC). The kitoperationalizes the detection, quantification, and interpretation of the synergisticbiomarker combination into a standardized clinical workflow.The diagnostic kit comprises:(1) Biomarker-Specific Primers and / or Probes:- Primers and / or hydrolysis probes configured for amplification and detectionof the following RNA biomarkers:- miR-1307-5p- CD44v6- KRT4- PD-L1- Designed for compatibility with reverse transcription quantitativepolymerase chain reaction (RT-qPCR) platforms to quantify expressionlevels with high sensitivity and specificity.(2) A Reagent System for Isolation of Extracellular Vesicles (EVs) andExtraction of Nucleic Acids from EVs:- Comprising reagents suitable for isolating RNA from biological samplesselected from saliva, plasma, tissue, or cellular fractions, including:- 500ul-1mL Extracellular vesicle precipitation reagent (polymerbased or PEG-based).- 500ul-1mL Lysis reagent comprising phenol and guanidineisothiocyanate for disruption of vesicles.- 200ul Chloroform for phase separation.- 7.5ul of 5mg / ml Nucleic acid co-precipitant (such as glycogen) toenhance RNA recovery.- 500ul- 1mL of 100% Isopropanol and 1ml of 70% ethanol-basedwashing solutions.- 20ul Nuclease-free water for RNA resuspension.- RNA yield and purity can be assessed using external instruments(bioanalyzer / fluorometer), not included within the kit.(3) Reverse Transcription and Quantitative PCR Reagents:- 20X MicroRNA-specific reverse transcription system (stem-loop primersand reverse transcriptase).- 20X mRNA-specific reverse transcription system (oligo-dT / randomprimers and reverse transcriptase).- 2X RT-qPCR master mix including AmpliTaq Gold DNA Polymerase,UP (Ultra Pure), dNTPs with dUTP, ROX Passive Reference andOptimized buffer components. Inclusion of the biomarker-specific primersand / or probes (250nM-900nM) for the amplification reactions.(4) Pre-Packaged Reference RNA Control:- Stabilized RNA sample derived from healthy salivary sources (100-1000ng / ul), serving as a baseline normalization control to calculate foldchange in biomarker expression.(5) Integrated Software Module:- Provided as a secure cloud-based interface or locally installableapplication, operable to:- Normalize raw expression data against housekeeping genes andreference control.- Calculate fold-change values of the four biomarkers.- Assign biomarker-specific scores based on expression thresholds:- miR-1307-5p ≥ 2.0-fold: Chemosensitivity / TherapeuticResponse Prediction.- CD44v6 ≥ 2.0-fold: High Relapse Risk / DiseaseAggressiveness.- KRT4 ≤ 1.0-fold: Chemosensitivity / Therapeutic ResponsePrediction.- PD-L1 ≥ 1.0-fold: Immunotherapy Suitability.- Stratify patients into clinical categories including:- Responders- Non-responders- High relapse risk- Immunotherapy-suitable- Integrate individual scores into a composite risk score using aweighted scoring algorithm of the software module. Here, the foldchanges provide the chemo score whereby the relapse score andimmuno score are generated. Once that is done, individual scores areintegrated to generate an overall risk score, based on which low,moderate, high or very high risk patients can be identified.- Additionally, derive a prognostic outcome assessment to classifypatients under 'Poor prognosis' based on combined biomarkerexpression trends indicative of adverse survival likelihood.- Generate structured clinical output reports for integration withelectronic medical record (EMR) systems or for direct use inoncology workflows.Operational Workflow Enabled by the Kit:1. Collection of a biological sample (preferably saliva) using a validated noninvasive collection device (optionally included).2. Isolation of extracellular vesicles and cellular fractions using theprecipitation and lysis reagents.3. RNA extraction and purification using the phase separation andprecipitation workflow.4. cDNA synthesis for miRNA and mRNA targets using the respective reversetranscription reagents.5. Quantification of biomarker expression levels via RT-qPCR usingincluded primers / probes and master mix.6. Data analysis and scoring using the software module to generate foldchange values and clinical risk stratification.7. Generation of diagnostic reports that assist clinicians in real-timetreatment monitoring and relapse prediction.Cross-Reference to Embodiment 1:The diagnostic kit of Embodiment 2 provides a clinically standardized means toexecute the biomarker signature composition described in Embodiment 1. Byfacilitating accurate measurement of miR-1307-5p, CD44v6, KRT4, and PD-L1expression from saliva-derived extracellular vesicles and enabling systematic datainterpretation through a scoring algorithm, the kit translates the biomarker panelinto a reproducible, actionable diagnostic tool for dynamic therapeuticmonitoring and early relapse detection in head and neck cancer patients.Embodiment 3: In Vitro Method for Monitoring Therapeutic Response andPredicting Relapse Using the Diagnostic KitEmbodiment 3 relates to an in vitro method for monitoring therapeutic responseand predicting relapse in patients with head and neck cancers, particularly oralsquamous cell carcinoma (OSCC), using the diagnostic kit as described inEmbodiment 2. This method enables non-invasive and repeatable monitoring ofbiomarker expression patterns, operationalizing the salivary biomarker panelof Embodiment 1 through a standardized diagnostic workflow.The method comprises the following steps:1. Sample Collection:Collecting a biological sample, preferably saliva (1-2ml), from thepatient using a validated non-invasive collection device optionallyincluded in the kit, said device optionally containing an RNA stabilizationbuffer to preserve RNA integrity.2. RNA Isolation:Isolating extracellular vesicles (EVs) from the collected biologicalsample, followed by RNA extraction from the EVs and / or cellularfractions using the reagent system provided in the kit. EV isolation may beperformed using polymer-based or PEG-based precipitation or equivalentmethods that preserve RNA integrity. The system comprising: - a polymer-based or PEG-based extracellular vesicle precipitationreagent (500ul-1ml) ; - phenol and guanidine isothiocyanate-based lysis reagent 500ul1mL; - chloroform 200ul , a nucleic acid co-precipitant (e.g.,glycogen)7.5ul of 5mg / ml , 500ul- 1mL of 100% isopropanol, 1ml of70% ethanol, and 20ul nuclease-free water.3. Reverse Transcription and Biomarker Quantification:Reverse transcribing the isolated RNA into cDNA using 20X miRNAand 20X mRNA-specific reverse transcription systems provided in the kit.Quantifying the expression levels of: - miR-1307-5p - CD44v6 - KRT4 - PD-L1using RT-qPCR with biomarker-specific primers / probes (250nM900nM) included in the kit.4. Data Normalization and Fold-Change Calculation:Processing the RT-qPCR expression data using the software moduleintegrated with the kit, wherein raw data are normalized using housekeepinggenes and compared against a reference RNA control derived from healthysaliva samples. Fold-change values are computed for each biomarker.5. Score Generation and Patient Stratification:Fold-change thresholds are interpreted as: - miR-1307-5p ≥ 2.0-fold - CD44v6 ≥ 2.0-fold - KRT4 ≤ 1.0-fold - PD-L1 ≥ 1.0-foldThe software module calculates biomarker-specific scores and integratesthem into a composite risk score via a weighted scoring algorithm.Patients are stratified into clinical categories: - Responder - Non-responder - High relapse risk - Immunotherapy-suitable By combining these individual scores and stratification, the inventiongenerates an Overall Risk Category classified as Low, Moderate, High, orVery High. Additionally, a prognostic outcome assessment is derived toclassify patients under 'Poor prognosis' based on the overall biomarkerexpression trends predictive of reduced survival and aggressive diseaseprogression.6. Clinical Reporting and Decision Support:Generating a structured clinical output report, integrated with ElectronicMedical Records (EMR) or usable in oncology workflows, enablingclinicians to make informed therapeutic decisions and proactive relapsesurveillance.Cross-reference to Embodiment 1:This method implements the synergistic biomarker panel of Embodiment 1through the diagnostic kit described in Embodiment 2, ensuring real-time, noninvasive, and reproducible assessment of therapeutic efficacy and relapse riskin head and neck cancer patients.Embodiment 4: In Vitro Method for Monitoring Therapeutic Response andPredicting Relapse Without Using the Diagnostic KitEmbodiment 4 discloses an in vitro method for monitoring therapeutic responseand predicting relapse in head and neck cancer patients, particularly OSCC,using standard laboratory reagents and workflows without relying on theproprietary diagnostic kit.The method comprises the following steps:1. Sample Collection:Collecting an unstimulated saliva sample from the patient using a noninvasive collection method, optionally employing an RNA stabilizationbuffer to preserve sample quality.2. RNA Isolation:Isolating extracellular vesicles (EVs) from the collected biological sample,followed by RNA extraction from the EVs and / or cellular fractions usingthe reagent system provided in the kit. EV isolation may be performed usingpolymer-based or PEG-based precipitation or equivalent methods thatpreserve RNA integrity. The system comprises of - polymer-based or PEG-based precipitation reagents for vesicleisolation; - phenol-guanidine-based lysis reagents, chloroform, glycogen (as anucleic acid co-precipitant), isopropanol, ethanol, and nuclease-free water.3. Reverse Transcription and Biomarker Quantification:Synthesizing cDNA from the extracted RNA using standard reversetranscription systems (stem-loop primers for miRNA and oligo(dT) orrandom primers for mRNA).Quantifying expression levels of: - miR-1307-5p - CD44v6 - KRT4 - PD-L1using RT-qPCR with custom-designed fluorescence-labeled sequencespecific probes.4. Fold-Change Calculation and Reference Control:Comparing the measured expression levels to baseline controls derived frommatched healthy salivary samples or publicly available reference datasets.Calculating fold-change values using the following thresholds: - miR-1307-5p ≥ 2.0-fold - CD44v6 ≥ 2.0-fold - KRT4 ≤ 1.0-fold - PD-L1 ≥ 1.0-fold. 5. Composite Scoring and Stratification:Integrating biomarker expression values using a structu red scoring logic(manual calculation or independent data analysis software) to categorizepatients into clinical categories: - Responder - Non-responder - High relapse risk - Immunotherapy-suitable By combining these individual scores and stratification, the inventiongenerates an Overall Risk Category classified as Low, Moderate, High, orVery High. Additionally, a prognostic outcome assessment is derived toclassify patients under 'Poor prognosis' based on the overall biomarkerexpression trends predictive of reduced survival and aggressive diseaseprogression.6. Interpretation and Clinical Application:Utilizing the scoring outcome to guide therapeutic decisions and relapsesurveillance strategies, enabling clinical actions even in the absence of theproprietary kit.Cross-reference to Embodiment 1:This method applies the salivary biomarker panel of Embodiment 1 throughlaboratory-standard workflows, ensuring broader accessibility of the technologyacross clinical and research settings, while maintaining the reproducibility,interpretability, and clinical relevance of the scoring system.VALIDATION STUDIES AND CLINICAL PERFORMANCEThe salivary biomarker panel and diagnostic kit of the present invention have beenvalidated through experimental studies and clinical observations, demonstratingtheir technical feasibility and clinical relevance in monitoring therapeutic responseand predicting relapse in head and neck cancer patients.The synergistic combination of miR-1307-5p, CD44v6, KRT4, and PD-L1 wasshown to provide a diagnostic advantage, where integrated expression profilingenabled accurate patient stratification into therapeutic response categories includingresponders, non-responders, high relapse risk, and immunotherapy suitability.Additionally, a prognostic outcome assessment was derived to classify patientsunder 'poor prognosis' based on unfavourable cumulative biomarker trends,reflecting reduced survival probability and aggressive disease behaviour.Case studies described in this specification illustrate the concordance betweenbiomarker-based predictions and actual treatment outcomes, underscoring theclinical utility of the invention.Reproducibility of the workflow was established across multiple sample runs, withconsistent RNA extraction, amplification, and scoring outputs. The panel's noninvasive nature, combined with its ability for repeat sampling and real-timemolecular monitoring, addresses critical gaps in existing diagnostic approaches,which rely on invasive biopsies and delayed imaging assessments.In comparison to prior art methods that focus on single markers or invasive sampletypes, the present invention delivers a validated biomarker composition tailored forsalivary extracellular vesicles, integrated with a scoring algorithm that translatesmolecular data into clinically actionable insights. This positions the invention as apractical and scalable diagnostic solution for dynamic cancer monitoring, offeringclear industrial applicability.INDUSTRIAL APPLICABILITYThe present invention offers a scalable, non-invasive diagnostic platform thatintegrates seamlessly into existing laboratory workflows and clinical practices. Byemploying saliva as a biofluid source and utilizing standardized RT-qPCRworkflows, the diagnostic kit enables widespread implementation across oncologyclinics, pathology laboratories, and research institutions. The modular kitcomponents, combined with a user-friendly software interface, facilitate easyintegration into electronic medical records (EMR) and decision-support systems.The invention's ability to provide repeatable, real-time monitoring of therapeuticresponse and relapse risk addresses a critical clinical gap, enhancing patient carethrough personalized treatment strategies. Its applicability spans initial diagnosis,ongoing therapy monitoring, and long-term surveillance, making it a versatile toolin head and neck cancer management.Given its compatibility with conventional laboratory equipment and potential foradaptation into point-of-care diagnostic formats, the invention demonstrates highindustrial applicability for commercial manufacturing, clinical deployment, andglobal adoption as a companion diagnostic platform.ADVANTAGES OF THE INVENTIONThe present invention provides several key advantages that address critical gaps incurrent diagnostic and monitoring approaches for head and neck cancers, includingoral squamous cell carcinoma (OSCC):1. Non-invasive, Repeatable SamplingUtilizes saliva-derived extracellular vesicles and / or cellular fractions,allowing dynamic, longitudinal monitoring without requiring tissue biopsiesor invasive procedures.2. Real-time Therapeutic Response AssessmentEnables early evaluation of chemotherapy and immunotherapyeffectiveness through molecular-level expression profiling, overcomingdelays inherent in imaging-based RECIST assessments.3. Combinatorial Biomarker SynergyLeverages a validated panel of miR-1307-5p, CD44v6, KRT4, and PD-L1,whose combined expression profiles yield superior diagnostic andprognostic accuracy compared to individual biomarkers.4. Actionable Scoring Algorithm for Clinical Decision SupportProvides a structured, weighted scoring system that integrates biomarkerexpression data into clinically interpretable risk categories, facilitatingevidence-based treatment adjustments.5. Predictive Monitoring of Relapse RiskDetects molecular indicators of relapse well before anatomical recurrenceis visible on imaging, enabling proactive intervention and personalizedfollow-up strategies.6. Improved Stratification for Immunotherapy SuitabilityOffers a non-invasive alternative to tissue biopsies for assessing PD-L1expression, supporting informed immunotherapy decision-making inotherwise inoperable patients.7. Scalability and Industrial ApplicabilityThe diagnostic kit is designed for seamless integration into standardmolecular laboratory workflows and is compatible with point-of-caredeployment, ensuring broad industrial applicability.8. Reduction of Unnecessary Treatment Cycles and ToxicityBy identifying non-responders early, the invention minimizes exposure toineffective therapies, optimizing patient outcomes and reducing healthcareburdens.TECHNICAL CONTRIBUTION AND ADVANCEMENT OVER PRIOR ARTDespite advancements in cancer treatments, a critical gap persisted in the ability topredict which patient would respond favorably to specific therapies. Oncologistsand clinical experts were often left without reliable tools to guide such lifeimpacting decisions. While treatment regimens for head and neck cancers werewell-established, the challenge of determining the right treatment for the rightpatient at the right time remained unresolved.With limited available technical resources and biomarker knowledge in practicalclinical workflows, there was an unmet need for a non-invasive, repeatable solutionthat could assist clinicians in dynamically assessing therapeutic response, relapserisk, and immunotherapy suitability. This invention fulfills that need by providinga synergistic biomarker panel and a reproducible diagnostic approach, empoweringclinicians with actionable insights to personalize patient care, reduce ineffectivetreatments, and intervene earlier to improve survival outcomes.The core technical advancement of the invention lies in operationalizing thesebiomarker signatures into a clinically usable platform that integrates into existingworkflows, ensuring that decision-making is no longer reliant on invasive biopsiesor delayed imaging assessments.
Claims
1. Salivary Biomarker Panel for Therapeutic Monitoring and Relapse Prediction in Head and Neck Cancers, comprising a combination of biomarkers selected from miR-1307-5p, CD44v6, KRT4, and PD-L1, wherein the combined expression pattern of said biomarkers provides a diagnostic modality operationalized through analytical detection, reference normalization, and risk scoring workflows, and exhibits a synergistic profile indicative of: (a) prognosis and survival prediction; (b) therapeutic efficacy of chemotherapy including platinum-based agents, taxols, 5-fluorouracil, doxorubicin, cetuximab, methotrexate, radiotherapy, and immunotherapy; (c) localized or metastatic disease status; and (d) relapse risk in head and neck cancer patients compared to healthy controls, and wherein the expression data stratifies patients into therapeutic response categories selected from responders, non-responders, high relapse risk, and immunotherapy-suitable, and further derives a prognostic outcome assessment indicative of poor prognosis based on cumulative biomarker trends., and wherein detection is performed at DNA, RNA, and / or protein levels.2.Salivary Biomarker Panel for Therapeutic Monitoring and Relapse Prediction in Head and Neck Cancers, embodied in a diagnostic kit, the kit comprising: - primers and / or probes specific to miR-1307-5p, CD44v6, KRT4, and PDL1, designed to amplify and detect the synergistic expression profile of the biomarker combination through reverse transcription quantitative polymerase chain reaction (RT-qPCR), sequencing, or immunoassay platforms; - a reagent system for extracellular vesicle (EV) isolation from biological samples selected from saliva, plasma, tissue, or cellular fractions, said reagent system comprising a polymer-based or polyethylene glycol (PEG)- based precipitation reagent or equivalent means to enrich EVs while preserving RNA integrity; - a reagent system for isolation of nucleic acids and / or proteins from biological samples selected from saliva, plasma, tissue, or cellular fractions, the reagent system comprising: (a) a polymer-based or polyethylene glycol-based extracellular vesicle precipitation reagent, (b) a phenol and guanidine isothiocyanate-based lysis reagent, (c) chloroform, (d) a nucleic acid co-precipitant, (e) isopropanol and ethanol-based washing solutions, and (f) nuclease-free water; - a pre-packaged reference control sample derived from healthy matched biological sources, for baseline normalization of biomarker expression data; - reverse transcription reagents comprising microRNA-specific and mRNAspecific primers and reverse transcriptase systems; - a quantitative detection system comprising thermostable DNA polymerase, deoxynucleotide triphosphates (dNTPs), magnesium chloride, probe-based detection chemistries, and reaction buffers optimized for amplification and quantification of said biomarkers; - optionally, a validated non-invasive saliva collection device containing an RNA stabilization buffer; and - a software module as claimed in claim 3, configured to process biomarker expression data for clinical stratification based on the synergistic expression profile of the biomarker signature panel, wherein said kit enables non-invasive sample collection and repeatable, longitudinal monitoring of biomarker expression patterns for patient stratification and clinical decision-making.3.Salivary Biomarker Panel for Therapeutic Monitoring and Relapse Prediction in Head and Neck Cancers, wherein the diagnostic kit as claimed in claim 2 comprises a software module provided as a secure cloud-based interface or as a locally installable application, and is configured for integration with electronic medical record (EMR) systems.4.Salivary Biomarker Panel for Therapeutic Monitoring and Relapse Prediction in Head and Neck Cancers, wherein the diagnostic kit as claimed in any one of claims 2 to 3 is configured to: - enable collection of a biological sample selected from saliva, plasma, tissue biopsy, or cellular fractions; - isolate extracellular vesicles from the saliva or plasma samples. - isolate nucleic acids and / or proteins from said sample using the provided reagents; - detect expression levels of miR-1307-5p, CD44v6, KRT4, and PD-L1 using RT-qPCR, sequencing, or immunoassay platforms; - process the expression data using the software module to compute foldchange values, calculate individual biomarker-specific scores, integrate the scores into a composite risk score; and - stratify the patient into therapeutic response categories selected from responders, non-responders, high relapse risk, and immunotherapy-suitable, and further derive a prognostic outcome assessment indicative of poor prognosis based on cumulative biomarker expression trends.5.Salivary Biomarker Panel for Therapeutic Monitoring and Relapse Prediction in Head and Neck Cancers, wherein an in vitro method is provided for diagnosing, monitoring therapeutic response, predicting relapse, and assessing prognosis in a patient using the diagnostic kit as claimed in any one of claims 2 to 4, the method comprising: - collecting a biological sample selected from saliva, plasma, tissue, or cellular fractions; - isolating extracellular vesicles from the saliva or plasma samples. - isolating nucleic acids and / or proteins using the kit reagents; - detecting expression levels of miR-1307-5p, CD44v6, KRT4, and PD-L1; - processing the expression data using the software module to compute foldchange values, calculate biomarker-specific scores, and generate a composite risk score; - stratifying the patient into therapeutic response categories selected from responders, non-responders, high relapse risk, and immunotherapy-suitable, and further deriving a prognostic outcome assessment reflecting poor prognosis; and - generating a structured clinical report for therapeutic decision-making, relapse surveillance, and survival prediction, wherein the method is configured for repeat assessments at multiple clinical timepoints for longitudinal monitoring.6.Salivary Biomarker Panel for Therapeutic Monitoring and Relapse Prediction in Head and Neck Cancers, wherein an in vitro method is provided comprising: - collecting a biological sample selected from saliva, plasma, tissue, or cellular fractions; - isolating nucleic acids (DNA / RNA) and / or proteins from said sample using laboratory-grade reagents; - quantifying expression levels of miR-1307-5p, CD44v6, KRT4, and PD-L1 using RT-qPCR, sequencing, or immunoassay techniques; - computing fold-change values relative to a reference control, wherein: (a) miR-1307-5p ≥ 2.0-fold indicates chemosensitivity and therapeutic response prediction, (b) CD44v6 ≥ 2.0-fold indicates high relapse risk and disease aggressiveness, (c) KRT4 ≤ 1.0-fold indicates chemosensitivity and therapeutic response prediction, and (d) PD-L1 ≥ 1.0-fold indicates immunotherapy suitability; - analyzing the quantified expression values through a structured computational scoring system configured to translate expression profiles into clinical stratification outputs, thereby classifying the patient into therapeutic response categories selected from responders, non-responders, high relapse risk, and immunotherapy-suitable, and further deriving a prognostic outcome assessment indicative of poor prognosis based on cumulative biomarker trends; - providing a structured clinical report indicative of patient outcome to aid therapeutic planning and monitoring, wherein the method enables repeat assessments over time for longitudinal monitoring.
7. The salivary biomarker panel as claimed in claims 1 to 6, wherein detection of the biomarkers is further applicable to biological samples selected from saliva, plasma, tissue, or cellular components including membrane, cytoplasm, nucleus, or nuclear membrane, at DNA, RNA, and / or protein levels.
